- Home
- FUTU vs SNN Comparison
FUTU vs SNN Comparison
Compare FUTU & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUTU
- SNN
- Stock Information
- Founded
- FUTU 2011
- SNN 1856
- Country
- FUTU Hong Kong
- SNN United Kingdom
- Employees
- FUTU N/A
- SNN N/A
- Industry
- FUTU Investment Bankers/Brokers/Service
- SNN Industrial Specialties
- Sector
- FUTU Finance
- SNN Health Care
- Exchange
- FUTU Nasdaq
- SNN Nasdaq
- Market Cap
- FUTU 12.2B
- SNN 10.8B
- IPO Year
- FUTU 2019
- SNN 1999
- Fundamental
- Price
- FUTU $89.08
- SNN $24.88
- Analyst Decision
- FUTU Strong Buy
- SNN Strong Buy
- Analyst Count
- FUTU 7
- SNN 1
- Target Price
- FUTU $72.97
- SNN N/A
- AVG Volume (30 Days)
- FUTU 3.3M
- SNN 962.8K
- Earning Date
- FUTU 11-19-2024
- SNN 08-01-2024
- Dividend Yield
- FUTU N/A
- SNN 3.01%
- EPS Growth
- FUTU 5.70
- SNN 39.77
- EPS
- FUTU 3.86
- SNN 0.35
- Revenue
- FUTU $1,216,035,584.00
- SNN $5,642,000,000.00
- Revenue This Year
- FUTU $29.76
- SNN $6.97
- Revenue Next Year
- FUTU $15.21
- SNN $5.46
- P/E Ratio
- FUTU $23.07
- SNN $34.83
- Revenue Growth
- FUTU 9.98
- SNN 5.48
- 52 Week Low
- FUTU $43.61
- SNN $23.65
- 52 Week High
- FUTU $130.50
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- FUTU 45.31
- SNN 32.09
- Support Level
- FUTU $87.15
- SNN $24.49
- Resistance Level
- FUTU $101.97
- SNN $25.09
- Average True Range (ATR)
- FUTU 5.53
- SNN 0.43
- MACD
- FUTU -1.50
- SNN -0.06
- Stochastic Oscillator
- FUTU 7.80
- SNN 19.77
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.